Is Ozempic a biologic?

No. Semaglutide is 31 amino acids, and the FDA treats 40 or fewer as a peptide regulated as a drug.

Why does the classification matter?

Drug generics file an ANDA showing bioequivalence. Biosimilars must show no clinically meaningful difference from the reference — far slower and costlier.

Can a synthetic generic reference a recombinant innovator?

Yes. The FDA accepts that sameness can be demonstrated across manufacturing routes — it is judged on the molecule.

GLP-1 & Incretin Science

Where a Peptide Stops Being a Drug

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

The FDA treats an alpha-amino acid polymer of 40 residues or fewer as a peptide, regulated as a drug. Anything longer is a protein, regulated as a biologic. Semaglutide is 31 residues, which places it on the drug side of that line.

Key facts

Threshold: 40 amino acids
40 or fewer: Peptide — regulated as a drug
More than 40: Protein — regulated as a biologic
Semaglutide: 31 residues — a drug
IGF-1 LR3: 83 residues — protein territory
Generic route for drugs: ANDA, bioequivalence
Generic route for biologics: Biosimilar, higher burden

Why a line has to be drawn somewhere

Small molecules can be characterised completely — every atom, every bond, confirmed by analysis. Large proteins cannot, because their behaviour depends on folding and post-translational modification that no analytical method fully captures. Regulation treats these differently, and peptides sit between them, so a boundary is needed and any boundary will be somewhat arbitrary.

Why 40 is a reasonable place for it

Below roughly that length a molecule can generally be made by chemical synthesis and characterised to the atom. Above it, synthesis becomes progressively harder — coupling efficiency compounds, so a 40-mer at 99% per step finishes around 68% full-length before purification — and folding starts to matter. The number marks where full characterisation stops being achievable.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

What the classification changes

The route a generic takes. A drug generic files an ANDA and demonstrates bioequivalence — that it delivers the same active ingredient at the same rate and extent. A biosimilar must demonstrate no clinically meaningful difference from the reference product, which usually requires comparative clinical work. The second is far slower and far more expensive.

The subtlety about manufacturing route

The FDA accepts that an ANDA applicant may show a proposed synthetic peptide is the same as the active ingredient in a previously approved peptide of recombinant DNA origin. So a generic can be chemically synthesised while the innovator was made recombinantly, and still be the same active ingredient. Sameness is judged on the molecule, not on how it was produced.

Where this catalogue falls either side of the line

Semaglutide at 31 residues and tirzepatide at 39 are both drugs. Retatrutide at 39 likewise. IGF-1 LR3 at 83 residues sits well past the threshold and would be handled as a biologic — which is consistent with it being a recombinant product with the impurity profile and folding concerns that come with one.

What none of this means for research material

Nothing supplied here holds any classification at all, because it holds no marketing authorisation. The drug-versus-biologic distinction governs how licensed medicines are approved and how their generics reach patients. It does not describe research chemicals, which sit outside that framework entirely.

Quick reference

Compound	Residues	Classification
Semaglutide	31	Peptide — drug
Tirzepatide	39	Peptide — drug
Retatrutide	39	Peptide — drug
IGF-1 LR3	83	Protein territory — biologic

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is Ozempic a biologic?: No. Semaglutide is 31 amino acids, and the FDA treats 40 or fewer as a peptide regulated as a drug.
Why does the classification matter?: Drug generics file an ANDA showing bioequivalence. Biosimilars must show no clinically meaningful difference from the reference — far slower and costlier.
Can a synthetic generic reference a recombinant innovator?: Yes. The FDA accepts that sameness can be demonstrated across manufacturing routes — it is judged on the molecule.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum